Biosig Technologies (NASDAQ:STEX) CIO Sells $208,451.77 in Stock

Biosig Technologies, Inc. (NASDAQ:STEX) CIO Mitchell Young Williams sold 263,863 shares of the firm’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $0.79, for a total transaction of $208,451.77. Following the transaction, the executive directly owned 3,037,648 shares of the company’s stock, valued at $2,399,741.92. The trade was a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Biosig Technologies Trading Up 10.0%

Shares of Biosig Technologies stock opened at $1.01 on Thursday. The company has a market capitalization of $182.95 million, a PE ratio of -0.11 and a beta of 1.58. Biosig Technologies, Inc. has a twelve month low of $0.70 and a twelve month high of $14.11. The business has a fifty day simple moving average of $1.44.

Biosig Technologies (NASDAQ:STEX) last announced its earnings results on Tuesday, March 31st. The company reported ($8.23) EPS for the quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Needham & Company LLC reduced their price objective on shares of Biosig Technologies from $12.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Wall Street Zen downgraded shares of Biosig Technologies from a “hold” rating to a “strong sell” rating in a research note on Sunday, April 5th. Finally, Weiss Ratings upgraded shares of Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $9.00.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.